BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eissa IH, Ibrahim MK, Metwaly AM, Belal A, Mehany ABM, Abdelhady AA, Elhendawy MA, Radwan MM, ElSohly MA, Mahdy HA. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Bioorg Chem 2021;107:104532. [PMID: 33334586 DOI: 10.1016/j.bioorg.2020.104532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Belal A, Abdel Gawad NM, Mehany ABM, Abourehab MAS, Elkady H, Al-Karmalawy AA, Ismael AS. Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 inhibitors. J Enzyme Inhib Med Chem 2022;37:1884-902. [PMID: 35801486 DOI: 10.1080/14756366.2022.2096019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Elwan A, Abdallah AE, Mahdy HA, Dahab MA, Taghour MS, Elkaeed EB, Mehany ABM, Nabeeh A, Adel M, Alsfouk AA, Elkady H, Eissa IH. Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation. Molecules 2022;27:5047. [PMID: 35956997 DOI: 10.3390/molecules27155047] [Reference Citation Analysis]
3 Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk AA, Husein DZ, Ibrahim IM, Metwaly AM, Eissa IH. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches. Processes 2022;10:1391. [DOI: 10.3390/pr10071391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Azab AE, Alesawy MS, Eldehna WM, Elwan A, Eissa IH. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation. Arch Pharm (Weinheim) 2022;:e2200133. [PMID: 35822666 DOI: 10.1002/ardp.202200133] [Reference Citation Analysis]
5 Yousef RG, Eldehna WM, Elwan A, Abdelaziz AS, Mehany ABM, Gobaara IMM, Alsfouk BA, Elkaeed EB, Metwaly AM, Eissa IH. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2. Molecules 2022;27:4079. [DOI: 10.3390/molecules27134079] [Reference Citation Analysis]
6 Elkaeed EB, Youssef FS, Eissa IH, Elkady H, Alsfouk AA, Ashour ML, El Hassab MA, Abou-seri SM, Metwaly AM. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease. IJMS 2022;23:6912. [DOI: 10.3390/ijms23136912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
7 Yousef RG, Ibrahim A, Khalifa MM, Eldehna WM, Gobaara IMM, Mehany ABM, Elkaeed EB, Alsfouk AA, Metwaly AM, Eissa IH. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J Enzyme Inhib Med Chem 2022;37:1389-403. [PMID: 35577416 DOI: 10.1080/14756366.2022.2070744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Alanazi MM, Elkady H, Alsaif NA, Obaidullah AJ, Alanazi WA, Al-hossaini AM, Alharbi MA, Eissa IH, Dahab MA. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. Journal of Molecular Structure 2022;1253:132220. [DOI: 10.1016/j.molstruc.2021.132220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
9 Hisham M, Hassan HA, Gomaa HA, Youssif BG, Hayallah AM, Abdel-aziz M. Structure-based design, synthesis and antiproliferative action of new quinazoline-4-one/chalcone hybrids as EGFR inhibitors. Journal of Molecular Structure 2022;1254:132422. [DOI: 10.1016/j.molstruc.2022.132422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Suleimen YM, Jose RA, Suleimen RN, Ishmuratova MY, Toppet S, Dehaen W, Alsfouk AA, Elkaeed EB, Eissa IH, Metwaly AM. Isolation and In Silico SARS-CoV-2 Main Protease Inhibition Potential of Jusan Coumarin, a New Dicoumarin from Artemisia glauca. Molecules 2022;27:2281. [PMID: 35408682 DOI: 10.3390/molecules27072281] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Eissa IH, Alesawy MS, Saleh AM, Elkaeed EB, Alsfouk BA, El-attar AMM, Metwaly AM. Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs. Molecules 2022;27:2287. [DOI: 10.3390/molecules27072287] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Haider K, Das S, Joseph A, Yar MS. An appraisal of anticancer activity with structure-activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review. Drug Dev Res 2022. [PMID: 35297084 DOI: 10.1002/ddr.21925] [Reference Citation Analysis]
13 Suleimen YM, Jose RA, Suleimen RN, Arenz C, Ishmuratova MY, Toppet S, Dehaen W, Alsfouk BA, Elkaeed EB, Eissa IH, Metwaly AM. Jusanin, a New Flavonoid from Artemisia commutata with an In Silico Inhibitory Potential against the SARS-CoV-2 Main Protease. Molecules 2022;27:1636. [PMID: 35268738 DOI: 10.3390/molecules27051636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
14 Suleimen YM, Jose RA, Suleimen RN, Arenz C, Ishmuratova M, Toppet S, Dehaen W, Alsfouk AA, Elkaeed EB, Eissa IH, Metwaly AM. Isolation and In Silico Anti-SARS-CoV-2 Papain-like Protease Potentialities of Two Rare 2-Phenoxychromone Derivatives from Artemisia spp. Molecules 2022;27:1216. [DOI: 10.3390/molecules27041216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
15 Zengin M, Unsal Tan O, Arafa RK, Balkan A. Design and Synthesis of New 2-Oxoquinoxalinyl-1,2,4-triazoles as Antitumor VEGFR-2 Inhibitors. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Mohammed SO, El Ashry SHE, Khalid A, Amer MR, Metwaly AM, Eissa IH, Elkaeed EB, Elshobaky A, Hafez EE. Expression, Purification, and Comparative Inhibition of Helicobacter pylori Urease by Regio-Selectively Alkylated Benzimidazole 2-Thione Derivatives. Molecules 2022;27:865. [PMID: 35164122 DOI: 10.3390/molecules27030865] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 Rayani RH, Soni JY, Parmar DR, Kusurkar RV, Eissae I, Metwaly AM, Khalil A, Zunjar V, Battula S, Niazi S. Identification of new pyrazolyl piperidine molecules as factor Xa inhibitors: Design, synthesis, in silico, and biological evaluation. Results in Chemistry 2022;4:100355. [DOI: 10.1016/j.rechem.2022.100355] [Reference Citation Analysis]
18 Elkady H, Elwan A, El-Mahdy HA, Doghish AS, Ismail A, Taghour MS, Elkaeed EB, Eissa IH, Dahab MA, Mahdy HA, Khalifa MM. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J Enzyme Inhib Med Chem 2022;37:397-410. [PMID: 34961427 DOI: 10.1080/14756366.2021.2015343] [Reference Citation Analysis]
19 Hagras M, Saleh MA, Ezz Eldin RR, Abuelkhir AA, Khidr EG, El-Husseiny AA, El-Mahdy HA, Elkaeed EB, Eissa IH. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies. J Enzyme Inhib Med Chem 2022;37:380-96. [PMID: 34923885 DOI: 10.1080/14756366.2021.2015342] [Reference Citation Analysis]
20 Khalifa MM, Al-Karmalawy AA, Elkaeed EB, Nafie MS, Tantawy MA, Eissa IH, Mahdy HA. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem 2022;37:299-314. [PMID: 34894955 DOI: 10.1080/14756366.2021.2007905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
21 Alsaif NA, Mahdy HA, Alanazi MM, Obaidullah AJ, Alkahtani HM, Al-Hossaini AM, Al-Mehizi AA, Elwan A, Taghour MS. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. Arch Pharm (Weinheim) 2021;:e2100359. [PMID: 34862634 DOI: 10.1002/ardp.202100359] [Reference Citation Analysis]
22 Paul GK, Mahmud S, Hasan MM, Zaman S, Uddin MS, Saleh MA. Biochemical and in silico study of leaf and bark extracts from Aphanamixis polystachya against common pathogenic bacteria. Saudi J Biol Sci 2021;28:6592-605. [PMID: 34764775 DOI: 10.1016/j.sjbs.2021.07.032] [Reference Citation Analysis]
23 Ran F, Li W, Qin Y, Yu T, Liu Z, Zhou M, Liu C, Qiao T, Li X, Yousef RG, Eissa IH, Khalifa MM. Inhibition of Vascular Smooth Muscle and Cancer Cell Proliferation by New VEGFR Inhibitors and Their Immunomodulator Effect: Design, Synthesis, and Biological Evaluation. Oxid Med Cell Longev 2021;2021:8321400. [PMID: 34745424 DOI: 10.1155/2021/8321400] [Reference Citation Analysis]
24 Eissa IH, Khalifa MM, Elkaeed EB, Hafez EE, Alsfouk AA, Metwaly AM. In Silico Exploration of Potential Natural Inhibitors against SARS-Cov-2 nsp10. Molecules 2021;26:6151. [PMID: 34684735 DOI: 10.3390/molecules26206151] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Eliwa EM, Frese M, Halawa AH, Soltan MM, Ponomareva LV, Thorson JS, Shaaban KA, Shaaban M, El-agrody AM, Sewald N. Metal-free domino amination-Knoevenagel condensation approach to access new coumarins as potent nanomolar inhibitors of VEGFR-2 and EGFR. Green Chemistry Letters and Reviews 2021;14:578-99. [DOI: 10.1080/17518253.2021.1981462] [Reference Citation Analysis]
26 Alsaif NA, Elwan A, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari AF, Albassam H, Mahdy HA, Taghour MS. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Mol Divers 2021. [PMID: 34460053 DOI: 10.1007/s11030-021-10303-6] [Reference Citation Analysis]
27 Alanazi MM, Alaa E, Alsaif NA, Obaidullah AJ, Alkahtani HM, Al-Mehizia AA, Alsubaie SM, Taghour MS, Eissa IH. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies. J Enzyme Inhib Med Chem 2021;36:1732-50. [PMID: 34325596 DOI: 10.1080/14756366.2021.1945591] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Parmar DR, Soni JY, Guduru R, Rayani RH, Kusurkar RV, Vala AG, Talukdar SN, Eissa IH, Metwaly AM, Khalil A, Zunjar V, Battula S. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorg Chem 2021;115:105206. [PMID: 34339975 DOI: 10.1016/j.bioorg.2021.105206] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Reddy NN, Hung SJ, Swamy MK, Sanjeev A, Rao VS, Rohini R, Raju AK, Bhaskar K, Hu A, Reddy PM. Synthesis and Rational Design of New Appended 1,2,3-Triazole-uracil Ensembles as Promising Anti-Tumor Agents via In Silico VEGFR-2 Transferase Inhibition. Molecules 2021;26:1952. [PMID: 33808444 DOI: 10.3390/molecules26071952] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Yousef RG, Sakr HM, Eissa IH, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, Elsohly MA, Abulkhair HS, El-adl K. New quinoxaline-2(1 H )-ones as potential VEGFR-2 inhibitors: design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. New J Chem 2021;45:16949-64. [DOI: 10.1039/d1nj02509k] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]